<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05075785</url>
  </required_header>
  <id_info>
    <org_study_id>PI2021_843_0135</org_study_id>
    <nct_id>NCT05075785</nct_id>
  </id_info>
  <brief_title>Covid-19 Respiratory Sequelae French Cohort</brief_title>
  <acronym>PNEUMOCOVID</acronym>
  <official_title>National Epidemiological Cohort to Evaluate Covid-19 Respiratory Sequelae: a French Pneumologist Collaboration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cabinet Medical valenciennes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Aix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>hopital privé de bois bernard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinique La Croix du Sud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopital Forcilles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopital d'instructions des armées</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Européen Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinique Saint Augustin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Delafontaine Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Troyes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier le Mans</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As the investigators need data on long term outcome of Covid-19, especially respiratory&#xD;
      sequelae, a national cohort is required. To better evaluate the potential respiratory&#xD;
      sequelae after SARS-CoV-2 infection, it is fundamental to include patients with different&#xD;
      management at the acute phase of the Covid-19: ambulatory management, hospitalization in non&#xD;
      ICU and in ICU units. That is why the investigators will conduct a national cohort study with&#xD;
      all components of french pneumology which will give the investigators the opportunity to&#xD;
      include patients in general hospital, in university hospital and in private structure. As it&#xD;
      is a &quot;real life&quot; study, the investigators will include all patients who will have a&#xD;
      consultation with a pneumologist for an evaluation 5 to 7 months after a Covid-19 infection&#xD;
      whatever their acute disease management. The investigators will collect all available data on&#xD;
      Covid-19 acute phase, on patients characteristics and comorbidities, on persistent symptoms&#xD;
      after Covid-19, on exams results during the outcome evaluation (CT-scan, 6 min walk test,&#xD;
      spirometry and DLCO, blood gas, VO2 max if realized).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Variation of vital capacity at 5 months after Covid-19 episode</measure>
    <time_frame>at 5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of vital capacity at 7 months after Covid-19 episode</measure>
    <time_frame>at 7 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>DLCO alteration at 5 months after Covid-19 episode</measure>
    <time_frame>at 5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>DLCO alteration at 7 months after Covid-19 episode</measure>
    <time_frame>at 7 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>desaturation during the &quot;6 min walk test&quot;</measure>
    <time_frame>at 5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>desaturation during the &quot;6 min walk test&quot;</measure>
    <time_frame>at 7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation of FEV1 spirometry parameters</measure>
    <time_frame>at 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of FEV1 spirometry parameters</measure>
    <time_frame>at 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of VC spirometry parameters</measure>
    <time_frame>at 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of VC spirometry parameters</measure>
    <time_frame>at 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of FVC spirometry parameters</measure>
    <time_frame>at 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of FVC spirometry parameters</measure>
    <time_frame>at 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of DLCO spirometry parameters</measure>
    <time_frame>at 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of DLCO spirometry parameters</measure>
    <time_frame>at 7 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <condition>Fibrosis</condition>
  <condition>Cohort</condition>
  <condition>Follow-up</condition>
  <condition>Sequelae</condition>
  <condition>Spirometry DLCO</condition>
  <eligibility>
    <study_pop>
      <textblock>
        As it is a &quot;real life&quot; study, the investigators will include all patients who will have a&#xD;
        consultation with a pneumologist for an evaluation 5 to 7 months after a Covid-19 infection&#xD;
        whatever their acute disease management.&#xD;
&#xD;
        This is a cohort study with collection of different data. The proposed follow-up of these&#xD;
        patients is the recommended follow-up of the french respiratory society. But, as it is a&#xD;
        real life study, no exams are mandatory.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults, older than 18&#xD;
&#xD;
          -  SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) in nasopharyngeal&#xD;
             swab in patients who are evaluated by a pneumologist 5 to 7 months after their&#xD;
             Covid-19 disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients for whom follow-up would be difficult owing to psychotic disorder&#xD;
&#xD;
          -  dementia&#xD;
&#xD;
          -  patients who have declined to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Claire ANDREJAK, Pr</last_name>
    <phone>03.22.08.79.98</phone>
    <email>andrejak.claire@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire ANDREJAK, PhD</last_name>
      <phone>+33322455960</phone>
      <email>andrejak.claire@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Stach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Estienne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Claude Grattepanche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Pierrre Perrigaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yann Bubien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine Marliere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rémi Macarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muriel Touboul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anatole Touzet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>cohort</keyword>
  <keyword>follow-up</keyword>
  <keyword>Sequelae</keyword>
  <keyword>spirometry DLCO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

